Omnicare — Q3 2010 Earnings Presentation
14 slides from Omnicare's earnings presentation, Oct 28, 2010
Slide 1: Supplemental Slides
Supplemental Slides
Slide 2: Forward-Looking Statements
Except for historical information discussed, the statements made today are forward- looking statements that involve risks and uncertainties. Investors are cautioned that such statements are only predictions and that actual events or results may differ materially. These forward-looking statements spe
Slide 3: Table of Contents
Third Quarter 2010 Highlights…………………………………………………..………...….. Operating Metrics - Script Data…………………………………………...……….…..…..… Operating Metrics - Bed Data…………………..……………………...…………………..…. Adjusted Gross Profit…………………………………………………...……...…..……...….. Adjusted Net Income………………………………………………………….…....………..... Ca
Slide 4: Third Quarter 2010 Highlights
Scripts dispensed increased 1.3% sequentially – One additional calendar day in 3Q 2010 as compared with 2Q 2010 – Number of beds served up sequentially – Utilization stable – Census was lower, although rate of decline improved from 2Q 2010 Qtr. ending number of beds served (1) up 32,000 sequentially
Slide 5: Operating Metrics - Script Data
(1) Excludes scripts dispensed in Omnicare’s specialty businesses and other non-institutional settings. (2) Generic prescriptions dispensed as a percentage of institutional pharmacy scripts. Operating Metrics - Script Data • Scripts up 1.3% sequentially largely due to: • one additional day in 3Q10 •
Slide 6: Operating Metrics - Bed Data
(1) Beds reported as capacity in institutional settings and unique patients serviced in non-institutional settings (clinic, retail, hospice) (2) PAP programs served by Omnicare’s specialty pharmacy business. Operating Metrics - Bed Data • Sequential improvements in organic additions, acquisitions an
Slide 7: Adjusted Gross Profit
(1) Each amount is reported independently. The sum of the individual amounts may not equal the sum of the separately presented amounts due to rounding. (2) Excludes discontinued operations. (3) Excludes special items. A reconciliation of this non-GAAP information has been attached to our press relea
Slide 8: Adjusted Net Income
(1) All numbers shown exclude special items and discontinued operations. A reconciliation of this non-GAAP information has been attached to our press release and is also available on our Web site under ‘Supplemental Financial Information’ from the ‘Investors’ page. (2) Each amount is reported indepe
Slide 9: Cash Flows
(1) Excludes benefit plan payments funded with rabbi trust assets. Cash Flows • Sequential increase in operating cash flow reflects increase in net income, working capital improvements and smaller interest payments in 3Q 2010. • Operating cash flow includes: • 2Q10 - Approximately $38 million in set
Slide 10: Cash Deployment
(1) During the second quarter of 2010, Omnicare issued $400 million of 7.75% Senior Subordinated Notes due 2020 and tendered $217 million of 6.75% Senior Subordinated Notes due 2013. (2) Cumulative % Returned = (YTD Dividends Paid + YTD Share Repurchases) / 12/31/09 Market Capitalization of $2,908.4
Slide 11: 2010 Guidance - No Change
Current Guidance (2) FY 2010 Adjusted EPS (3) $2.00 to $2.10 $2.00 to $2.10 FY 2010 Cash Flow from Operations (4) $400M to $450M $400M to $450M (1) Guidance provided on August 5, 2010. (2) Guidance provided on October 28, 2010. (3) Excludes special items and discontinued operations. (4) Excludes dis
Slide 12: Appendix
Appendix
Slide 13: Working Capital Management
In # of Days In # of Days (1) (1) At 9/30/10, includes approximately $85 million in receivables, or the equivalent of approximately 6 DSOs, related to past due receivables owed to the Company by a group of customers whom the Company has commenced legal action against (and recently reached a prelimin
Slide 14: Selected Branded Drug Patent Expirations
(1) All generic launches are subject to change due to litigation or pediatric exclusivity. (2) Drugs already launched shown in gray and italics 3Q 2010 4Q 2010 FY 2011 Effexor XR Ambien CR Fazaclo Exelon CAPS Prevacid Soltabs Femara Diastat Rectal Aricept IR Gabitril Lovenox Primaxin Inj. Levaquin M